Patents by Inventor Sang Youn Hwang
Sang Youn Hwang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220380437Abstract: A physiologically active polypeptide-immunoglobulin Fc fragment conjugate and a method for making the conjugate are disclosed. The conjugate contains a physiologically active polypeptide linked via a non-peptidyl linker to an immunoglobulin Fc fragment having an FcRn-binding region and maintains the intrinsic binding affinity of the immunoglobulin Fc fragment. A method of maintaining the intrinsic binding affinity of the conjugate for FcRn, and a composition containing the conjugate, which maintains the intrinsic binding affinity of the immunoglobulin Fc fragment for FcRn are also disclosed.Type: ApplicationFiled: August 3, 2022Publication date: December 1, 2022Applicant: HANMI PHARM. CO., LTD.Inventors: Sang Youn HWANG, Jong Soo Lee, Sung Hee Hong, In Young Choi, Sung Youb Jung, Se Chang Kwon
-
Patent number: 10435459Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves in vivo sustainability and stability.Type: GrantFiled: February 5, 2019Date of Patent: October 8, 2019Assignee: Hanmi Pharm. Co., Ltd.Inventors: Sang Youn Hwang, Jin Young Kim, Seung Su Kim, In Young Choi, Sung Youb Jung, Se Chang Kwon
-
Publication number: 20190169271Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves in vivo sustainability and stability.Type: ApplicationFiled: February 5, 2019Publication date: June 6, 2019Inventors: Sang Youn Hwang, Jin Young Kim, Seung Su Kim, In Young Choi, Sung Youb Jung, Se Chang Kwon
-
Patent number: 10253082Abstract: The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.Type: GrantFiled: January 20, 2015Date of Patent: April 9, 2019Assignee: HANMI PHARM. CO., LTDInventors: Sung Youb Jung, Sang Youn Hwang, Euh Lim Oh, Sung Hee Park, Hyun Uk Kim, Chang Ki Lim, Se Chang Kwon
-
Patent number: 10233230Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves in vivo sustainability and stability.Type: GrantFiled: September 16, 2015Date of Patent: March 19, 2019Assignee: Hanmi Pharm. Co., Ltd.Inventors: Sang Youn Hwang, Jin Young Kim, Seung Su Kim, In Young Choi, Sung Youb Jung, Se Chang Kwon
-
Patent number: 10188703Abstract: A composition for preventing or treating diabetes mellitus includes insulin and a GLP-1/glucagon dual agonist. The composition can inhibit the weight gain and reduce the danger of hypoglycemia due to the administration of insulin, lower the administration dose and greatly improve the compliance of drugs through a combined administration of a long-acting insulin conjugate and a long-acting GLP-1/glucagon dual agonist conjugate. In addition, the long-acting insulin conjugate and the long-acting GLP-1/glucagon dual agonist conjugate can improve the in vivo sustainability and stability because an insulin and a GLP-1/glucagon dual agonist are linked to the immunoglobulin Fc region via a non-peptidyl linker. A method for preventing or treat diabetes mellitus includes administration of the insulin and a GLP-1/glucagon dual agonist.Type: GrantFiled: June 1, 2015Date of Patent: January 29, 2019Assignee: HANMI PHARM. CO., LTD.Inventors: Sung Youb Jung, Sang Youn Hwang, Seung Su Kim, In Young Choi, Se Chang Kwon
-
Publication number: 20180256731Abstract: An insulin analog has a reduced insulin titer and a reduced insulin receptor binding affinity compared to the native form for the purpose of increasing the blood half-life of insulin. A conjugate is prepared by linking the insulin analog and a carrier. A long-acting formulation includes the conjugate.Type: ApplicationFiled: May 18, 2018Publication date: September 13, 2018Applicant: HANMI PHARM. CO., LTDInventors: Sang Youn Hwang, Yong Ho Huh, Jin Young Kim, Sung Hee Hong, In Young Choi, Sung Youb Jung, Se Chang Kwon, Dae Jin Kim, Hyun Uk Kim, Myung Hyun Jang, Seung Su Kim
-
Patent number: 10046061Abstract: Provided are an insulin conjugate having improved insulin receptor binding affinity and increased activity, in which a non-peptidyl polymer and an immunoglobulin Fc region are site-specifically linked to an amino acid residue of the insulin beta chain excluding the N-terminus thereof via a covalent bond, a long-acting formulation including the same, and a preparation method thereof. The insulin conjugate of the present invention is used to provide an insulin formulation which exhibits a remarkably increased in vivo activity of the peptide.Type: GrantFiled: February 26, 2014Date of Patent: August 14, 2018Assignee: HANMI PHARM. CO., LTDInventors: Myung Hyun Jang, Dae Jin Kim, Sang Youn Hwang, Hyun Uk Kim, Sung Youb Jung, Se Chang Kwon
-
Publication number: 20170298117Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves in vivo sustainability and stability.Type: ApplicationFiled: September 16, 2015Publication date: October 19, 2017Applicant: HANMI PHARM. CO., LTD.Inventors: Sang Youn HWANG, Jin Young KIM, Seung Su KIM, In Young CHOI, Sung Youb JUNG, Se Chang KWON
-
Publication number: 20170226175Abstract: The present invention relates to an insulinotropic peptide derivative with a modified N-terminal charge and a pharmaceutical composition including the same. Specifically, the insulinotropic peptide derivative is characterized in that the N-terminal positive charge of the insulinotropic peptide is modified to a neutral or net negative charge at neutral pH. The insulinotropic peptide derivative according to the present invention is rapidly dissociated from the GLP-1 receptor owing to the above modification in the N-terminal charge, and exhibits enhanced insulinotropic ability and blood glucose-lowering activity compared to the native insulinotropic peptide while maintaining its stability in blood. Accordingly, the insulinotropic peptide derivative of the present invention is very useful for the treatment of type 2 diabetes.Type: ApplicationFiled: April 25, 2017Publication date: August 10, 2017Applicant: HANMI PHARM. CO., LTD.Inventors: Sung Youb JUNG, Sang Youn HWANG, In Young CHOI, Sung Hee PARK, Se Chang KWON
-
Publication number: 20170196943Abstract: A composition for preventing or treating diabetes mellitus includes insulin and a GLP-1/glucagon dual agonist. The composition can inhibit the weight gain and reduce the danger of hypoglycemia due to the administration of insulin, lower the administration dose and greatly improve the compliance of drugs through a combined administration of a long-acting insulin conjugate and a long-acting GLP-1/glucagon dual agonist conjugate. In addition, the long-acting insulin conjugate and the long-acting GLP-1/glucagon dual agonist conjugate can improve the in vivo sustainability and stability because an insulin and a GLP-1/glucagon dual agonist are linked to the immunoglobulin Fc region via a non-peptidyl linker. A method for preventing or treat diabetes mellitus includes administration of the insulin and a GLP-1/glucagon dual agonist.Type: ApplicationFiled: June 1, 2015Publication date: July 13, 2017Applicant: HANMI PHARM. CO., LTD.Inventors: Sung Youb JUNG, Sang Youn HWANG, Seung Su KIM, In Young CHOI, Se Chang KWON
-
Patent number: 9663565Abstract: The present invention relates to an insulinotropic peptide derivative with a modified N-terminal charge and a pharmaceutical composition including the same. Specifically, the insulinotropic peptide derivative is characterized in that the N-terminal positive charge of the insulinotropic peptide is modified to a neutral or net negative charge at neutral pH. The insulinotropic peptide derivative according to the present invention is rapidly dissociated from the GLP-1 receptor owing to the above modification in the N-terminal charge, and exhibits enhanced insulinotropic ability and blood glucose-lowering activity compared to the native insulinotropic peptide while maintaining its stability in blood. Accordingly, the insulinotropic peptide derivative of the present invention is very useful for the treatment of type 2 diabetes.Type: GrantFiled: January 3, 2014Date of Patent: May 30, 2017Assignee: HANMI PHARM. CO., LTD.Inventors: Sung Youb Jung, Sang Youn Hwang, In Young Choi, Sung Hee Park, Se Chang Kwon
-
Publication number: 20170101455Abstract: The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.Type: ApplicationFiled: January 20, 2015Publication date: April 13, 2017Applicant: HANMI PHARM. CO., LTD.Inventors: Sung Youb JUNG, Sang Youn HWANG, Euh Lim OH, Sung Hee PARK, Hyun Uk KIM, Chang Ki LIM, Se Chang KWON
-
Publication number: 20160152684Abstract: The present invention relates to a physiologically active polypeptide-immunoglobulin Fc fragment conjugate, which comprises a physiologically active polypeptide linked via a non-peptidyl linker to an immunoglobulin Fc fragment having an FcRn-binding region and maintains the intrinsic binding affinity of the immunoglobulin Fc fragment, a method for preparing the conjugate, a method of maintaining the intrinsic binding affinity of the conjugate for FcRn, and a composition comprising the conjugate, which maintains the intrinsic binding affinity of the immunoglobulin Fc fragment for FcRn.Type: ApplicationFiled: July 14, 2014Publication date: June 2, 2016Applicant: HANMI PHARM. CO., LTD.Inventors: Sang Youn HWANG, Jong Soo LEE, Sung Hee HONG, In Young CHOI, Sung Youb JUNG, Se Chang KWON
-
Publication number: 20160008483Abstract: The present invention relates to an insulin analog that has a reduced insulin titer and a reduced insulin receptor binding affinity compared to the native form for the purpose of increasing the blood half-life of insulin, a conjugate prepared by linking the insulin analog and a carrier, a long-acting formulation including the conjugate, and a method for preparing the conjugate.Type: ApplicationFiled: February 26, 2014Publication date: January 14, 2016Applicant: HANMI PHARM. CO., LTDInventors: Sang Youn HWANG, Yong Ho HUH, Jin Young KIM, Sung Hee HONG, In Young CHOI, Sung Youb JUNG, Se Chang KWON, Dae Jin KIM, Hyun Uk KIM, Myung Hyun JANG, Seung Su KIM
-
Publication number: 20160000931Abstract: Provided are an insulin conjugate having improved insulin receptor binding affinity and increased activity, in which a non-peptidyl polymer and an immunoglobulin Fc region are site-specifically linked to an amino acid residue of the insulin beta chain excluding the N-terminus thereof via a covalent bond, a long-acting formulation including the same, and a preparation method thereof. The insulin conjugate of the present invention is used to provide an insulin formulation which exhibits a remarkably increased in vivo activity of the peptide.Type: ApplicationFiled: February 26, 2014Publication date: January 7, 2016Applicant: HANMI PHARM. CO., LTD.Inventors: Myung Hyun JANG, Dae Jin KIM, Sang Youn HWANG, Hyun Uk KIM, Sung Youb JUNG, Se Chang KWON
-
Publication number: 20150359859Abstract: The present invention relates to a method for inactivating viruses in a composition comprising blood coagulation factor VII, and more particularly, to a method for inactivating viruses comprising adding a surfactant to a composition comprising blood coagulation factor VII or a derivative thereof and a method for preparing a virus-inactivated composition comprising blood coagulation factor VII or the derivative thereof.Type: ApplicationFiled: February 3, 2014Publication date: December 17, 2015Applicant: HANMI PHARM. CO., LTD.Inventors: Dae Jin KIM, Byung Sun LEE, Seung Su KIM, Sang Youn HWANG, In Young CHOI, Se Chang KWON
-
Publication number: 20150329611Abstract: The present invention relates to an insulinotropic peptide derivative with a modified N-terminal charge and a pharmaceutical composition including the same. Specifically, the insulinotropic peptide derivative is characterized in that the N-terminal positive charge of the insulinotropic peptide is modified to a neutral or net negative charge at neutral pH. The insulinotropic peptide derivative according to the present invention is rapidly dissociated from the GLP-1 receptor owing to the above modification in the N-terminal charge, and exhibits enhanced insulinotropic ability and blood glucose-lowering activity compared to the native insulinotropic peptide while maintaining its stability in blood. Accordingly, the insulinotropic peptide derivative of the present invention is very useful for the treatment of type 2 diabetes.Type: ApplicationFiled: January 3, 2014Publication date: November 19, 2015Applicant: HANMI PHARM. CO., LTD.Inventors: Sung Youb JUNG, Sang Youn HWANG, In Young CHOI, Sung Hee PARK, Se Chang KWON
-
Publication number: 20140357843Abstract: The present invention relates to immunoglobulin Fc variants having an increased binding affinity for FcRn, which is characterized by including one or more amino acid modifications selected from the group consisting of 307S, 308F, 380S, 380A, 428L, 429K, 430S, 433K and 434S (this numbering is according to the EU index) in the constant region of a native immunoglobulin Fc fragment. Owing to the high binding affinity for FcRn, the immunoglobulin Fc variants according to the present invention show more prolonged in vivo half-life, and thus can be used for the preparation of a long-acting formulation of protein drugs.Type: ApplicationFiled: December 28, 2012Publication date: December 4, 2014Applicant: HANMI SCIENCE CO., LTDInventors: Euh Lim Oh, Yong Ho Huh, Sang Youn Hwang, In Young Choi, Sung Youb Jung, Se Chang Kwon